CoChat

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

Open access
Hantschel, Oliver, Rix, Uwe, Superti-Furga, Giulio · 2008 · Leukemia & Lymphoma

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Following the initial success of imatinib as frontline therapy for chronic myeloid leukemia (CML), several second-generation therapeutics have been developed with increased potency and the ability to inhibit the majority of imatinib-resistant mutations. Here, we review the current knowledge about the target specificity of the two new inhibitors nilotinib and dasatinib in comparison to imatinib, including the recent large-scale chemical proteomics screens.

Overview

Integrity signals

Registry

Crossref · 10.1080/10428190801896103

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 17 references

Research works printed but not linked: 1

  1. le Coutre P, Blood

Cited by

Items 101–200 of 286

Metadata

Authors
Hantschel, O., Rix, U., & Superti-Furga, G.
Affiliations
Austrian Academy of Sciences (AT)
Venue
Leukemia & Lymphoma
Published
2008-01
Volume
49
Issue
4
Pages
615-619
ISSN
  • 1026-8022 (ISSN-L)
  • 1042-8194
  • 1029-2403
OpenAlex
W2034862875
Cited by
256
References
17
Citations by year
2026: 2 · 2025: 6 · 2024: 4 · 2023: 14 · 2022: 15 · 2021: 14 · 2020: 21 · 2019: 10 · 2018: 16 · 2017: 19 · 2016: 10 · 2015: 17 · 2014: 15 · 2013: 19 · 2012: 23
FWCI
11.04
Type
journal article
Language
en
Open access
Locations
  • Leukemia & lymphoma/Leukemia and lymphoma (publishedVersion)
  • PubMed (publishedVersion)
  • Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
  • Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
Topics
  • Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
BCR-ABL tyrosine kinase inhibitors, imatinib, nilotinib, dasatinib, chronic myeloid leukemia, target specificity, imatinib resistance, second-generation tyrosine kinase inhibitors
MeSH terms
Imatinib Mesylate, Dasatinib, Benzamides, Humans, Piperazines, Pyrimidines, Thiazoles, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Drug Delivery Systems, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.